Amanta Healthcare Limited has received formal disclosure from Bandhan Mutual Fund regarding a substantial acquisition that pushed the fund's shareholding above the 5% regulatory threshold. The acquisition, completed on March 25, 2026, through open market purchases, triggered mandatory disclosure requirements under SEBI regulations.

Official SEBI Disclosure Filing

Bandhan AMC Limited, as the investment manager of Bandhan Mutual Fund, formally notified BSE Limited on March 27, 2026, about the substantial acquisition. The disclosure was filed under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, with Vijayalaxmi Khatri, Head – Legal & Compliance, signing the official communication.

Acquisition Details

Bandhan Mutual Fund, operating through its scheme Bandhan Small Cap Fund, acquired 21,603 equity shares of Amanta Healthcare on March 25, 2026. This purchase increased the fund's total shareholding from 19,24,676 shares to 19,46,279 shares, representing an increase from 4.9568% to 5.0124% of the company's paid-up capital.

Company Capital Structure

Amanta Healthcare's equity share capital remains unchanged at INR 38,82,93,510, comprising 3,88,29,351 equity shares of face value Rs. 10 each, fully paid up. The total diluted share capital also stands at the same level, indicating no outstanding convertible securities or warrants.

Regulatory Compliance and Exchange Notification

The fund has confirmed it does not belong to the promoter or promoter group of Amanta Healthcare. The company has been listed on both BSE Limited and National Stock Exchange of India Limited. The formal disclosure ensures compliance with listing requirements and transparency norms, providing shareholders with timely information about significant shareholding changes. The acquisition represents institutional interest in the healthcare company, with the mutual fund crossing the important 5% threshold that mandates public disclosure.

Amanta Healthcare Limited has submitted a disclosure under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, regarding an open market purchase of equity shares by an insider.

Transaction Details

Ms. Dypal Jain, who is an immediate relative to Director Shri Nitin Jain, acquired 15,675 equity shares of the company through open market purchases conducted between March 19, 2026, and March 24, 2026.

Shareholding Position

Prior to this transaction, Ms. Dypal Jain held 1 equity share representing a negligible percentage of the company's total shareholding. Following the acquisition of 15,675 additional shares, her total shareholding has increased to 15,676 equity shares, representing 0.04% of the company's equity capital.

Regulatory Compliance

The company received the disclosure in Form 'C' pursuant to Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, dated March 25, 2026. The disclosure was submitted to both BSE Limited and National Stock Exchange of India Limited on March 26, 2026, by Company Secretary and Compliance Officer Nikhita Dinodia.

The transaction represents a market purchase executed through regular trading mechanisms on both major Indian stock exchanges, demonstrating compliance with insider trading disclosure requirements under SEBI regulations.